We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Panel Favors Chelsea’s Northera Drug Despite Some Reservations
FDA Panel Favors Chelsea’s Northera Drug Despite Some Reservations
February 24, 2012
An FDA advisory panel voted 7–4 with one abstention to recommend approval of Chelsea Therapeutics’ Northera, arguing a high unmet medical need outweighs safety concerns and a lack of long-term efficacy data.